The formation of b-amyloid (Ab) plaques is a critical neurodegenerative change in Alzheimer disease (AD). We designed and synthesized novel boron dipyrromethane (BODIPY)-based Ab probes (BAPs) and evaluated their utility for near-infrared fluorescence imaging of Ab plaques in the brain. In binding experiments in vitro, BAPs showed high affinity for synthetic Ab aggregates (K d 5 18-149 nM).
high photostability, a high fluorescent quantum yield, a high extinction coefficient, and pH or environmental insensitivity. Therefore, BODIPY has been used as a scaffold for fluorescent probes for various targets, candidates for solid-state solar concentrators, and materials for incorporation into electroluminescent devices. [34] [35] [36] [37] We previously reported a BODIPY-based molecular probe (BAP-1) with a dimethylamino styryl group that plays an important role in binding to Ab aggregates. 38 BAP-1 showed good affinity for synthetic Ab aggregates in vitro (K d 5 44 nM), penetrated the blood-brain barrier, and selectively labeled Ab plaques in the mouse brain. However, BAP-1 showed shorter wavelengths of excitation/emission at 614/648 nm than are appropriate for optical imaging in vivo. Consequently, further optimization of the substituted groups in the BODIPY scaffold was needed to achieve clearer imaging of Ab plaques in vivo.
A previous report showed that the wavelength of BODIPY derivatives could be lengthened by replacing a phenyl group with a thiophenyl or furanyl group. 35 Several reports have suggested that such a change in some Abbinding compounds does not affect affinity for Ab aggregates. 19, 23, 28, [39] [40] [41] Thus, we planned to substitute the dimethylaminophenyl group in BAP-1 with a dimethylaminothiophenyl group (BAP-2), a dimethylaminofuranyl group (BAP-3), a dimethylaminophenylthiophenyl group (BAP-4), and a dimethylaminophenylfuranyl group (BAP-5) ( Figure 1 ). In the present study, we synthesized four novel BODIPY-based Ab probes (BAP-2-5) and evaluated their biologic potential as NIRF probes for imaging Ab plaques.
Methods

General
All reagents were obtained commercially and used without further purification unless otherwise indicated. 1 H nuclear magnetic resonance (NMR) and 13 C NMR spectra were obtained on a JNM-LM400 (JEOL Ltd., Tokyo, Japan) spectrometer with tetramethylsilane as an internal standard. Coupling constants are reported in hertz. Multiplicity was defined by singlet (s), doublet (d), and multiplet (m). Mass spectra (MS) and high resolution mass spectra (HRMS) electron ionization (EI) were obtained on a GCMS-QP2010 Plus (Shimadzu Corp., Kyoto, Japan) or JMS-GC mate mass spectrometer (JEOL Ltd., Tokyo, Japan).
A solution of pyrrole 2-carboxyaldehyde (368 mg, 3.87 mmol) and 2,4-dimethylpyrrole (368 mg, 3.87 mmol) in CHCl 3 (10 mL) was cooled to 0uC. After POCl 3 (360 mL) was added with caution, the mixture was stirred at room temperature for 2 hours. BF 3 OEt 2 (3 mL) and Et 3 N (3 mL) were added sequentially, and the resulting mixture was stirred at room temperature for 10 minutes. The solution was washed with H 2 O and dried with Na 2 SO 4 . The solvent was removed, and the residue was purified by silica gel column chromatography (hexane:ethyl acetate 5 2:1) to give 308 mg of 1 (36.1%). 1 
5-(Dimethylamino)thiophene-2-carbaldehyde (2)
5-Bromo-2-thiophenecarboxaldehyde (1.0 g, 5.23 mmol) was dissolved in H 2 O (3 mL) with dimethylaniline (1.64 mL, 15.69 mmol). The mixture was stirred under reflux for 6 hours, and then cooled to room temperature. After extraction with chloroform, the organic phase was dried over Na 2 SO 4 and filtered. The solvent was removed, and the residue was purified by silica gel chromatography 
5-(Dimethylamino)furan-2-carbaldehyde (3)
The same reaction as described above to prepare 2 was used, and 496 mg of 3 was obtained in a 49.9% yield from 5-bromo-2-furaldehyde. 1 
4,4-Difluoro
1 (288 mg, 1.31 mmol) and 2 (203 mg, 1.31 mmol) were dissolved in toluene (10 mL) with piperidine (917 mL) and AcOH (917 mL). The mixture was stirred under reflux for 2 hours. After the mixture had cooled to room temperature, H 2 O was added and extracted with chloroform. The organic phase was dried over Na 2 SO 4 and filtered. The solvent was removed, and the residue was purified by silica gel chromatography (chloroform) to give 26 mg of 4 (5.6%). 1 
The same reaction as described above to prepare 4 was used, and 131 mg of 5 was obtained in a 29.2% yield from 1 and 2. 1 
5-(4-(Dimethylamino)phenyl)thiophene-2carbaldehyde (6)
To a solution of 5-formyl-2-thiophene boronic acid (390 mg, 2.5 mmol), 4-bromo-N,N-dimethylaniline (500 mg, 2.5 mmol), and Pd(PPh 3 ) 4 (50 mg) in dioxane (15 mL) was added in a solution of aqueous Na 2 CO 3 (10 mL) under a nitrogen atmosphere. The mixture was stirred overnight under reflux. The reaction was quenched by the addition of H 2 O. Following extraction with chloroform, the combined organic extract was dried over anhydrous MgSO 4 and filtered. The solvent was removed, and the residue was washed with hexane to give 258 mg of 6 (44.7%). 1 
5-(4-(Dimethylamino)phenyl)furan-2-carbaldehyde (7)
The same reaction as described above to prepare 6 was used, and 131 mg of 5 was obtained in a 49.3% yield from 4-bromo-N,N-dimethylaniline and 5-formyl-2-furan boronic acid. 1 
The same reaction as described above to prepare 2 was used, and 21.5 mg of 8 was obtained in a 10.9% yield from 1 and 6. 1 
The same reaction as described above to prepare 2 was used, and 73 mg of 9 was obtained in a 38.9% yield from 1 and 3. 1 
Fluorescence Measurement Using Ab(1-42) and Bovine Serum Albumin
A solid form of Ab(1-42) was purchased from Peptide Institute (Osaka, Japan). Aggregation was carried out by gently dissolving the peptide (0.25 mg/mL) in phosphatebuffered saline (PBS) (pH 7.4). The solution was incubated at 37uC for 42 hours with gentle and constant shaking. A mixture (10% EtOH) containing BAPs (10 mM) and Ab(1-42) aggregates (0, 5, and 10 mM) or bovine serum albumin (BSA) (45 mg/mL) was incubated at room temperature for 30 minutes. After incubation, fluorescence emission spectra of BAP-2, BAP-3, BAP-4, and BAP-5 were collected with excitation at 656, 671, 643, and 654 nm (Infinite M200PRO, TECAN).
Measurement of the Constant for Binding of Ab Aggregates In Vitro
A mixture (100 mL of 10% EtOH) containing BAP-2, BAP-3, BAP-4, and BAP-5 (final concentration 0-3.75 mM) and
Ab aggregates (final concentration 2.2 mM) was incubated at room temperature for 30 minutes. Fluorescence intensity at 707 nm for BAP-2, 729 nm for BAP-3, 705 nm for BAP-4, and 709 nm for BAP-5 was recorded (excitation: 656, 671, 643, and 654 nm, respectively). The K d binding curve was generated by Prism 4.0 software.
In Vitro Fluorescent Staining of Mouse Brain Sections
The experiments with animals were conducted in accordance with our institutional guidelines and approved by the Kyoto University Animal Care Committee. A Tg2576 transgenic mouse (female, 28 months old) was used as the AD model. After the animal was sacrificed by decapitation, the brain was removed and sliced into serial sections 10 mm thick. Each slide was incubated with a 50% EtOH solution (100 mM) of BAP-2, BAP-3, BAP-4, and BAP-5 for 10 minutes. For blocking experiments, the brain sections were incubated with BAP-2 (10 mM) in the presence of AV-45 (100 mM). The sections were washed in 50% EtOH for 1 minute two times and examined using a microscope (BIOREVO BZ-9000, Keyence Corp., Osaka, Japan) equipped with a Cy5 for BAP-2, a Cy5.5 for BAP-3 and BAP-4, and a BAP-5 filter set. Thereafter, the serial sections were also stained with thioflavin S, a pathologic dye commonly used for staining Ab plaques in the brain, and examined using a microscope equipped with a GFP filter set.
Ex Vivo Imaging of Brains from Normal Mice
A mixed solution consisting of 20% DMSO and 80% propylene glycol (100 mL) of BAP-2, BAP-4, and BAP-5 (500 mM) was injected intravenously directly into the tail of ddY mice (5 weeks old). The mice (n 5 4-5 for each time point) were sacrificed at 2, 10, 30, and 60 minutes postinjection. The brain was removed and weighed, and fluorescence images of brains were acquired with an IVIS Spectrum imaging system (Caliper Life Sciences Inc., Hopkinton, MA) with a 0.1-second exposure (f-stop 5 2) and a customized filter set (excitation, 640 nm; emission, 700 nm). The fluorescence intensity in each region of interest covering an entire tissue was expressed as p/s/cm 2 /sr after the subtraction of background signals obtained in a region of interest set over an area without any tissue.
Ex Vivo Imaging of a Brain Slice from Tg2576 Mouse
A 25-month-old Tg2576 mouse and a 23-month-old wild-type mouse were intravenously injected with 100 mL of BAP-2 (500 mM, 20% DMSO, 80% propylene glycol). After 2 hours, the mice were sacrificed and the brain was removed. Fluorescence images of the brain were acquired with an IVIS Spectrum imaging system with a 0.1-second exposure (f-stop 5 2) and a customized filter set (excitation, 640 nm; emission, 700 nm). Thereafter, the brain was frozen in powdered dry ice. The frozen blocks were sliced into serial sections, 20 mm thick, and examined using a microscope equipped with a Cy5 filter set. After being immersed in 50% EtOH for 15 minutes, the same sections were stained with thioflavin S and observed with a GFP filter set.
Results and Discussion
Chemistry
The synthesis of the BAPs (BAP-2, BAP-3, BAP-4, and BAP-5) is outlined in Figure 2 . The formation of the BODIPY backbone (1) was accomplished by a previously reported method. 38 The dimethylamino derivatives 2 and 3 were produced by a one-pot process. 42 
Fluorescence Properties
First, we evaluated fluorescent properties. The BAPs exhibited absorption, excitation, and emission wavelengths of 623 to 665 nm, 636 to 663 nm, and 704 to 723 nm, respectively, with a good quantum yield (4.3-11.4%) in CHCl 3 (Table 1 and Figure 3) . These results suggest that the new BODIPY derivatives have better properties than BAP-1, indicating that they may enable clearer Ab imaging. Furthermore, in a solution containing Ab aggregates, their fluorescence intensity increased with the concentration of the aggregates, indicating affinity for Ab aggregates (Figure 4 ). Conversely, we found no significant change in fluorescence during the incubation with BSA, indicating that there is little interaction between BAPs and BSA. Although BAPs had very high quantum yields, they demonstrated weak fluorescence spectra. We think that the major reason for the weak signal is the difference of solvent. To evaluate the affinity for Ab aggregates, we measured the apparent binding constant (K d ) by conducting a saturation assay ( Table 2 ). The K d values estimated for BAP-2, BAP-3, BAP-4, and BAP-5 were 55, 149, 27, and 18 nM, respectively, suggesting high affinity for Ab aggregates. These values were in the same range as the K d of BAP-1 (44.1 nM), reported previously. 38 Furthermore, compared to the other Ab probes reported previously, their affinity was higher than that of AOI-987 (K d 5 220 nM) 21 and similar to that of CRANAD-2 (K d 5 38.9 nM) 26 and THK-265 (K d 5 97 nM). 24 
Neuropathologic Staining of Mouse Brain Sections
To confirm the affinity of BAPs for Ab plaques in the mouse brain, neuropathologic fluorescent staining with BAP-2, BAP-3, BAP-4, and BAP-5 was carried out using brain sections from Tg2576 mice ( Figure 5 ). Tg2576 mice are specifically engineered to overproduce Ab plaques in the brain. Therefore, they have been frequently used to evaluate the specific binding of Ab plaques in experiments in vitro and in vivo. 5, 12, 14, 43 BAP-2, BAP-3, BAP-4, and BAP-5 clearly stained the plaques, as reflected by the high affinity for Ab aggregates in in vitro binding assays. The staining pattern was consistent with that observed with thioflavin S, a dye commonly used to stain Ab plaques. The results suggest that these compounds show specific binding to Ab plaques in the mouse brain. Furthermore, the fluorescent staining with BAP-2 (see Figure 5A ) could be blocked to a large extent with an excess of the cold AV-45 (see Figure 5I ), confirming the specific binding of BAP-2 to Ab plaques.
Biodistribution Experiments
To test the uptake into and washout from the brain, we determined the fluorescence intensity in the brain after the injection of BAP-2, BAP-4, and BAP-5 into a normal mouse except BAP-3, which showed lower binding to Ab aggregates than any other probe ( Figure 6 ). Given that BAPs emit weak fluorescence even when they do not bind to Ab plaques, they showed a fluorescence signal even in the brains of normal mice. All three compounds penetrated the blood-brain barrier. Notably, BAP-2 showed high initial uptake at 2 minutes postinjection, and thereafter, the fluorescence that accumulated in the brain was rapidly eliminated. Conversely, BAP-4 and BAP-5 persisted in the brain. Given that normal brain tissue has no Ab plaques to trap the agent, washout from the brain should be fast, providing a higher signal to noise ratio in Molecular Imaging of Ab Plaques with NIR BODIPY-Based Fluorescent Probes the AD brain. These results suggest that BAP-2 has the most highly desirable properties for Ab imaging probes among the BAPs in this report. Consequently, we selected BAP-2 for further characterization in vivo.
Ex Vivo Imaging of Tg2576 Mouse Brain and Wild-Type Mouse Brain
To evaluate the potential of BAP-2 in living brain tissue, we carried out experiments ex vivo using a Tg2576 mouse (25-month-old female) and a wild-type mouse (23month-old female). The fluorescence in whole brains removed at 2 hours postinjection of BAP-2 was much higher in the Tg2576 mouse than in the wild-type mouse (Figure 7) . To confirm the presence of BAP-2, we prepared frozen sections from both brains and observed them with a fluorescence microscope. The brain sections from the Tg2576 mouse showed distinctive staining of Ab plaques by BAP-2, whereas those from the wild-type mouse showed no such staining (Figure 8 ). Ab plaques were confirmed to be present by staining the sections with thioflavin S. The results suggest that BAP-2 penetrated the blood-brain barrier and selectively labeled the Ab plaques in the mouse brain, as reflected by the biodistribution experiments and in vitro binding assays. We carried out in vivo imaging experiments using Tg2576 mice and agematched controls. The absorbance, excitation, and emission wavelengths of BAP-2 were suitable for NIRF imaging; however, we could not find a significant difference in fluorescence intensity between the two groups because BAP-2 showed higher accumulation in the scalp than in the brain in both groups. This may be attributable to the marked binding of BAP-2 to lipids in the scalp because it is well known that some BODIPY derivatives can serve as a lipid-staining agent. 44 This also indicates that in vivo imaging is feasible using new NIR compounds with a low affinity for lipids. Therefore, appropriate structural modifications of BODIPY derivatives may lead to the development of more useful probes for the in vivo imaging of Ab plaques in the brain. Furthermore, if we can obtain three-dimensional images with fluorescence imaging systems such as IVIS Spectrum CT, the problem observed in in vivo imaging with BAP-2 will be resolved.
As we mentioned at the beginning, in principle, a good NIRF probe for Ab plaques should have the following properties: (1) a suitable wavelength of absorption, excitation, and emission (. 650 nm); (2) the ability to rapidly enter the brain after intravenous injection; (3) specific labeling of the Ab plaques with rapid clearing of the unbound dye; and (4) on binding to Ab plaques, it should significantly change its fluorescence properties. BAP-2 fulfilled these prerequisites as an in vivo optical imaging probe targeting Ab plaques, whereas few reported probes have satisfied these criteria.
Conclusion
We successfully designed and synthesized novel BAPs for NIRF imaging in vivo. In binding experiments in vitro, BAP-2, BAP-3, BAP-4, and BAP-5 showed high affinity for Ab aggregates. These compounds clearly stained Ab plaques in the mouse brain, reflecting their affinity for Ab aggregates in vitro. In biodistribution experiments using normal mice, BAP-2, BAP-4, and BAP-5 displayed good uptake into the brain. In addition, ex vivo fluorescent staining of brain sections from Tg2576 mice after the injection of BAP-2 showed selective binding of Ab plaques with little nonspecific binding. These findings suggest that further optimization of BAPs leads to the development of NIRF imaging probes for the detection of Ab plaques and the drug screening for AD.
